Skip to main content

Table 1 Summary of the 14 observational studies assessing the treatment outcomes for patients with MDR-TB under DOTS-Plus that were included in the meta-analysis (n = 14)

From: Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies

Study authors

Study location

Study period

Study design

Sample size

HIV (%)

Treatment duration

Treatment regimen

Kurbatova et al. [16]

Five countriesa

2000–2003

RC

1768

1.6

 

Individualized

Singla et al. [17]

India

2002–2006

RC

126

24–27 months

Standardized

Keshavjee et al. [18]

Russia

2000–2004

RC

579

0.9

≥24 months

Individualized

Riekstina et al. [19]

Latvia

2002

RC

75

24 months

Individualized

Cox et al. [20]

Karakalpakstan, Uzbekistan

2003–2005

PC

87

≥24 months

Individualized

Shin et al. [21]

Russia

2000–2002

RC

244

0

≥12 months

Individualized

Holtz et al. [22]

Latvia

2000

RC

167

12–18 months after conversion

Individualized

Leimane et al. [23]

Latvia

2000

RC

204

0.5

12–18 months after conversion

Individualized

Tupasi et al. [24]

Philippines

1999–2002

PC

149

≥24 Months

Individualized

Arora et al. [25]

India

2002–2005

RC

52

24 months

Standardized

Mitnick et al. [26]

Peru

1999–2002

RC

651

1.5

15 months after conversion

Standardized

Jain et al. [27]

India

2009

PC

130

24 months

Standardized

Farley et al. [28]

South Africa

2000–2004

PC

757

38

12–18 months after conversion

Standardized

Van Deun et al. [14]

Bangladesh

1997–1999

RC

58

24 months

Standardized

  1. aThe five countries were Peru, Latvia, Estonia, Russia, and the Philippines